Insight Molecular Diagnostics Inc.
IMDXNASDAQHealthcare● Active
$5.98
+$0.26(+4.60%)
Market Cap$160592473
P/E Ratio—
52W High$8.51
52W Low$2.33
Insight Molecular Diagnostics Inc. (IMDX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IMDX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($50.22M) | ($60.66M) | ($27.78M) | ($72.90M) | ($64.10M) |
| Depreciation & Amort. | $2.20M | $1.56M | $1.68M | $5.22M | $4.21M |
| Stock-Based Comp. | $2.22M | $1.91M | $6.57M | $10.04M | $6.84M |
| Change in Working Capital | $2.73M | ($1.32M) | ($3.97M) | ($1.94M) | $0.15M |
| Net Cash from Operations | ($22.18M) | ($20.71M) | ($23.32M) | ($45.57M) | ($35.94M) |
| Investing Activities | |||||
| Capital Expenditure | ($3.19M) | ($0.52M) | ($0.28M) | ($4.34M) | ($2.25M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.37M | $0.00M | $0.00M |
| Net Cash from Investing | ($3.19M) | ($0.51M) | ($0.93M) | ($4.34M) | ($13.96M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | ($0.24M) |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($0.51M) | ($0.20M) | ($0.12M) | ($1.43M) | ($1.53M) |
| Net Cash from Financing | $28.07M | $20.43M | $12.19M | $35.81M | $78.36M |
| Free Cash Flow | |||||
| Free Cash Flow | ($25.37M) | ($21.23M) | ($23.61M) | ($49.91M) | ($38.19M) |
| FCF Margin %(computed) | -625.62% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Insight Molecular Diagnostics Inc. data
About Insight Molecular Diagnostics Inc. (IMDX) Cash Flow Statement
Insight Molecular Diagnostics Inc. generated operating cash flow of ($0.02B) and free cash flow of ($0.03B) for 2025 — a FCF margin of -625.62%. Capital expenditure was ($0.00B).
Frequently asked questions
IMDX · 4 questionsInsight Molecular Diagnostics Inc. generated free cash flow of ($0.03B) for 2025, down 19.5% year-over-year.
IMDX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10